Type of security: Stock
Sector: Capital Goods
The data is delayed by 15 minutes.
IART is in the long-term up 319% in 13 years.
Description: Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neurosurgery, U.S. Extremities, U.S. Instruments, U.S. Spine and Other, and International. Its orthopedics products include specialty metal implants for surgery of the extremities, shoulder, and spine; orthobiologic products for repair and grafting of bone, including demineralized bone products, collagen ceramic matrices, and synthetic bone grafting solutions; dermal regeneration products and tissue-engineered wound dressings; and nerve and tendon repair products. The company also offers spinal fusion technologies comprising integrated interbody fusion devices, minimally invasive solutions, and deformity correction products; and neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devi
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||1%||Sales Growth - Q/Q||-7.34%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||2.59%||ROE||5.84%||ROI||3.02%|
|Current Ratio||4.12||Quick Ratio||2.28||Long Term Debt/Equity||1.55||Debt Ratio||0.18|
|Gross Margin||62.28%||Operating Margin||7.77%||Net Profit Margin||4.24%||Dividend Payout Ratio|
|Cash From Financing Activities||30.45 M||Cash From Investing Activities||-18.74 M||Cash From Operating Activities||49.74 M||Gross Profit||157.54 M|
|Net Profit||5 M||Operating Profit||13.95 M||Total Assets||1.64 B||Total Current Assets||608.25 M|
|Total Current Liabilities||155.75 M||Total Debt||654.14 M||Total Liabilities||926.17 M||Total Revenue||244.08 M|
|High 52 week||65.87||Low 52 week||42.62||Last close||61.85||Last change||2.11%|
|RSI||53.53||Average true range||1.4||Beta||0.67||Volume||390.34 K|
|Simple moving average 20 days||2.95%||Simple moving average 50 days||2.07%||Simple moving average 200 days||13.93%|
|Performance Week||6.77%||Performance Month||1.76%||Performance Quart||14.66%||Performance Half||17.45%|
|Performance Year||-3.1%||Performance Year-to-date||37.14%||Volatility daily||1.4%||Volatility weekly||3.13%|
|Volatility monthly||6.42%||Volatility yearly||22.25%||Relative Volume||322.8%||Average Volume||416.06 K|
|New High||New Low|
2021-04-03 05:30:56 | Is Integra LifeSciences Holdings Corporation's NASDAQ:IART 8.8% ROE Worse Than Average?
2021-04-01 16:15:00 | Integra LifeSciences Appoints Shaundra Clay as Director
2021-03-31 10:41:02 | Here's Why You Should Retain Integra LifeSciences IART Stock
2021-03-31 09:08:01 | Integra's IART Neurosurgery Rebounds Despite Supply Issues
2021-03-22 05:33:09 | Veeva VEEV Partners With Impel, Boosts Cloud-Based Offerings Revised
2021-03-20 11:30:03 | Integra IART Down 3% Since Last Earnings Report: Can It Rebound?
2021-03-10 09:24:02 | Integra IART Neurosurgery Grows Sequentially Amid Supply Woe
2021-02-19 08:00:00 | Integra LifeSciences Announces Participation in Upcoming Investor Conferences
2021-02-18 16:00:43 | Integra Lifesciences Holdings Corp IART Q4 2020 Earnings Call Transcript
2021-02-18 07:47:04 | Recap: Integra Lifesciences Q4 Earnings
2021-02-18 06:30:00 | Integra LifeSciences Holdings Corp. to Host Earnings Call
2021-02-12 07:50:12 | Veeva VEEV Partners With Impel, Boosts Cloud-Based Offerings
2021-02-09 02:00:47 | Calculating The Intrinsic Value Of Integra LifeSciences Holdings Corporation NASDAQ:IART
2021-01-21 09:29:02 | Integra IART Acquires Acell, Focuses on Regenerative Space
2021-01-20 08:40:00 | Integra LifeSciences Completes the Acquisition of ACell, Inc.
2021-01-15 08:35:01 | Integra IART Preliminary Q4 Reported Sales Show Recovery
2021-01-06 13:30:06 | NEOGEN NEOG Fortifies Global Position via Megazyme Buyout
2021-01-06 09:29:02 | Hologic HOLX Completes SOMATEX Buyout, Expands Portfolio
2021-01-05 10:02:03 | Integra IART Sells Unprofitable Arm to Focus on Core Business
2020-12-31 09:26:02 | Integra IART Hits New 52-Week High: What's Driving It?
2020-12-29 10:36:03 | Integra IART to Buy ACell, Expand Regenerative Capability
2020-12-21 16:01:00 | Integra LifeSciences to Present at 39th Annual J.P. Morgan Healthcare Conference
2020-12-16 08:00:00 | Integra LifeSciences Announces Definitive Agreement to Acquire ACell, Inc.
2020-12-15 20:39:51 | Is IART A Good Stock To Buy Now?
2020-12-08 12:46:05 | Should Value Investors Pick Integra LifeSciences IART Now?
2020-11-27 11:31:04 | Integra IART Up 24% Since Last Earnings Report: Can It Continue?
2020-11-11 08:28:58 | How Much Is Integra LifeSciences Holdings' NASDAQ:IART CEO Getting Paid?
2020-10-29 11:20:03 | Integra IART Q3 Earnings Surpass Estimates, Margins Up
2020-10-28 17:30:38 | Integra Lifesciences Holdings Corp IART Q3 2020 Earnings Call Transcript
2020-10-28 07:30:11 | Integra LifeSciences IART Tops Q3 Earnings and Revenue Estimates
2020-10-28 07:21:19 | Integra Lifesciences: Q3 Earnings Insights
2020-10-28 06:30:00 | Integra LifeSciences Holdings Corp. to Host Earnings Call
2020-10-28 06:00:00 | Integra LifeSciences Reports Third Quarter 2020 Financial Results
2020-10-21 12:32:04 | Earnings Preview: Integra LifeSciences IART Q3 Earnings Expected to Decline
2020-10-14 11:40:03 | IART vs. ABMD: Which Stock Is the Better Value Option?
2020-10-08 03:37:15 | Integra Jumps 6% On Raised 3Q Sales Outlook
2020-10-07 10:42:02 | Integra IART Preliminary Q3 Results Show Recovery in Sales
2020-10-07 09:00:59 | Hedge Funds Dipping Their Toes Into Integra Lifesciences Holdings Corp IART
2020-09-29 11:56:00 | Integra to Sell Orthopedics Line to Smith & Nephew for $240M
2020-09-20 20:00:00 | Market Digest: THRM, IART